Checchi Capital Advisers’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $412K | Buy |
4,555
+44
| +1% | +$3.69K | 0.02% | 402 |
|
|
2026
Q1 | $361K | Buy |
4,511
+815
| +22% | +$67.2K | 0.02% | 421 |
|
|
2025
Q4 | $315K | Buy |
3,696
+25
| +0.7% | +$2.05K | 0.02% | 421 |
|
|
2025
Q3 | $285K | Sell |
3,671
-486
| -12% | -$38K | 0.01% | 451 |
|
|
2025
Q2 | $325K | Sell |
4,157
-222
| -5% | -$16.6K | 0.02% | 432 |
|
|
2025
Q1 | $317K | Buy |
4,379
+12
| +0.3% | +$859 | 0.02% | 447 |
|
|
2024
Q4 | $323K | Buy |
4,367
+136
| +3% | +$9.52K | 0.02% | 423 |
|
|
2024
Q3 | $279K | Sell |
4,231
-2,488
| -37% | -$181K | 0.02% | 460 |
|
|
2024
Q2 | $621K | Buy |
6,719
+212
| +3% | +$18.8K | 0.03% | 275 |
|
|
2024
Q1 | $622K | Sell |
6,507
-26
| -0.4% | -$2.18K | 0.05% | 279 |
|
|
2023
Q4 | $498K | Buy |
6,533
+701
| +12% | +$48.8K | 0.04% | 310 |
|
|
2023
Q3 | $404K | Sell |
5,832
-1,084
| -16% | -$87.1K | 0.04% | 336 |
|
|
2023
Q2 | $652K | Buy |
6,916
+223
| +3% | +$19.4K | 0.06% | 238 |
|
|
2023
Q1 | $554K | Buy |
6,693
+649
| +11% | +$51K | 0.05% | 264 |
|
|
2022
Q4 | $451K | Sell |
6,044
-1,205
| -17% | -$92.9K | 0.05% | 297 |
|
|
2022
Q3 | $599K | Sell |
7,249
-274
| -4% | -$26.4K | 0.06% | 230 |
|
|
2022
Q2 | $756K | Sell |
7,523
-708
| -9% | -$73.3K | 0.07% | 206 |
|
|
2022
Q1 | $969K | Buy |
8,231
+3,101
| +60% | +$348K | 0.08% | 163 |
|
|
2021
Q4 | $665K | Buy |
5,130
+58
| +1% | +$6.76K | 0.06% | 203 |
|
|
2021
Q3 | $574K | Sell |
5,072
-46
| -0.9% | -$5.25K | 0.06% | 218 |
|
|
2021
Q2 | $530K | Buy |
5,118
+77
| +2% | +$7.26K | 0.05% | 242 |
|
|
2021
Q1 | $422K | Buy |
5,041
+219
| +5% | +$18.5K | 0.04% | 273 |
|
|
2020
Q4 | $440K | Buy |
4,822
+322
| +7% | +$26.7K | 0.05% | 261 |
|
|
2020
Q3 | $359K | Sell |
4,500
-539
| -11% | -$42.1K | 0.04% | 262 |
|
|
2020
Q2 | $348K | Sell |
5,039
-367
| -7% | -$26.1K | 0.04% | 264 |
|
|
2020
Q1 | $340K | Sell |
5,406
-543
| -9% | -$39.2K | 0.03% | 230 |
|
|
2019
Q4 | $463K | Buy |
5,949
+234
| +4% | +$18.3K | 0.06% | 217 |
|
|
2019
Q3 | $419K | Sell |
5,715
-897
| -14% | -$63K | 0.05% | 227 |
|
|
2019
Q2 | $407K | Sell |
6,612
-42
| -0.6% | -$2.54K | 0.05% | 237 |
|
|
2019
Q1 | $424K | Buy |
6,654
+579
| +10% | +$33K | 0.05% | 214 |
|
|
2018
Q4 | $310K | Sell |
6,075
-930
| -13% | -$47.1K | 0.04% | 256 |
|
|
2018
Q3 | $407K | Buy |
7,005
+84
| +1% | +$4.11K | 0.05% | 254 |
|
|
2018
Q2 | $336K | Sell |
6,921
-216
| -3% | -$10.1K | 0.04% | 274 |
|
|
2018
Q1 | $332K | Buy |
7,137
+105
| +1% | +$4.56K | 0.04% | 272 |
|
|
2017
Q4 | $264K | Buy |
+7,032
| New | +$258K | 0.04% | 324 |
|
|
2017
Q3 | – | Sell |
-5,589
| Closed | -$220K | – | 390 |
|
|
2017
Q2 | $220K | Buy |
+5,589
| New | +$204K | 0.02% | 337 |
|
|
2016
Q4 | – | Sell |
-6,087
| Closed | -$245K | – | 391 |
|
|
2016
Q3 | $245K | Sell |
6,087
-30
| -0.5% | -$1.13K | 0.03% | 317 |
|
|
2016
Q2 | $203K | Buy |
6,117
+228
| +4% | +$7.8K | 0.02% | 339 |
|
|
2016
Q1 | $173K | Buy |
+5,889
| New | +$162K | 0.04% | 388 |
|
Other funds holding EW
WT
Checchi Capital Advisers's EW Position: Q2 2026 in Review
Checchi Capital Advisers increased its Edwards Lifesciences (EW) stake by 0.98% in Q2 2026, buying an estimated $3.69K and bringing the position to 4,555 shares worth $412K. The position accounts for 0.02% of the portfolio, ranked #402.
Checchi Capital Advisers first reported a position in EW in Q1 2016 and has held it in 39 quarters since. The position peaked at $969K in Q1 2022. 774 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Checchi Capital Advisers held 4,555 shares of Edwards Lifesciences worth $412K as of Q2 2026.
- Checchi Capital Advisers bought 44 Edwards Lifesciences shares in Q2 2026, an estimated $3.69K.
- Edwards Lifesciences made up 0.02% of Checchi Capital Advisers's portfolio in Q2 2026, its #402 holding.
- Checchi Capital Advisers first reported a position in Edwards Lifesciences in Q1 2016 and has held it in 39 quarters since.
- Checchi Capital Advisers's Edwards Lifesciences position peaked at $969K in Q1 2022.
- 774 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Checchi Capital Advisers's 13F filing for Q2 2026, filed 4 Aug 2026.